Other Species / Isoforms
  RALA (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
K7-ub
_MAANKPkGQNsLAL
0 4
RALA (human) _MAANKPkGQNsLAL K7-ub
RALA (mouse) _MAANKPkGQNsLAL K7-ub
RALA (rat) _MAANKPKGQNSLAL K7
S11-p
NKPkGQNsLALHKVI
0 8
RALA (human) NKPkGQNsLALHKVI S11-p
RALA (mouse) NKPkGQNsLALHKVI S11-p
RALA (rat) NKPKGQNSLALHKVI S11
S22-p
HKVIMVGsGGVGKSA
0 3
RALA (human) HKVIMVGsGGVGKSA S22-p
RALA (mouse) HKVIMVGSGGVGKSA S22
RALA (rat) HKVIMVGSGGVGKSA S22
Y43-p
YDEFVEDyEPTKADS
Upstream
0 10
Treatment
  • gefitinib
  • imatinib
RALA (human) YDEFVEDyEPTKADS Y43-p
RALA (mouse) YDEFVEDYEPTKADS Y43
RALA (rat) YDEFVEDYEPTKADS Y43
Y51-p
EPTKADSyRKKVVLD
0 1
RALA (human) EPTKADSyRKKVVLD Y51-p
RALA (mouse) EPTKADSYRKKVVLD Y51
RALA (rat) EPTKADSYRKKVVLD Y51
Y75-p
DTAGQEDyAAIRDNY
0 11
RALA (human) DTAGQEDyAAIRDNY Y75-p
RALA (mouse) DTAGQEDYAAIRDNY Y75
RALA (rat) DTAGQEDYAAIRDNY Y75
K128-ub
PFLLVGNksDLEDkR
0 1
RALA (human) PFLLVGNksDLEDkR K128-ub
RALA (mouse) PFLLVGNKSDLEDkR K128
RALA (rat) PFLLVGNKSDLEDkR K128
S129-p
FLLVGNksDLEDkRQ
0 1
RALA (human) FLLVGNksDLEDkRQ S129-p
RALA (mouse) FLLVGNKSDLEDkRQ S129
RALA (rat) FLLVGNKSDLEDkRQ S129
K134
NksDLEDKRQVsVEE
0 1
RALA (human) NksDLEDKRQVsVEE K134
RALA (mouse) NKSDLEDKRQVSVEE K134
RALA (rat) NKSDLEDkRQVSVEE K134-ac
K134-ub
NksDLEDkRQVsVEE
0 3
RALA (human) NksDLEDkRQVsVEE K134-ub
RALA (mouse) NKSDLEDkRQVSVEE K134-ub
RALA (rat) NKSDLEDKRQVSVEE K134
S138-p
LEDkRQVsVEEAkNR
0 1
RALA (human) LEDkRQVsVEEAkNR S138-p
RALA (mouse) LEDkRQVSVEEAkNR S138
RALA (rat) LEDkRQVSVEEAKNR S138
K143-ub
QVsVEEAkNRAEQWN
0 4
RALA (human) QVsVEEAkNRAEQWN K143-ub
RALA (mouse) QVSVEEAkNRADQWN K143-ub
RALA (rat) QVSVEEAKNRADQWN K143
Y153-p
AEQWNVNyVETSAkT
0 2
RALA (human) AEQWNVNyVETSAkT Y153-p
RALA (mouse) ADQWNVNYVETSAkT Y153
RALA (rat) ADQWNVNYVETSAKT Y153
K159-ub
NyVETSAkTRANVDK
0 7
RALA (human) NyVETSAkTRANVDK K159-ub
RALA (mouse) NYVETSAkTRANVDK K159-ub
RALA (rat) NYVETSAKTRANVDK K159
S183-p
RARKMEDsKEKNGKK
Upstream
Downstream
2 1
Effects on Modified Protein
  • enzymatic activity, induced
Effects on Biological Processes:
  • carcinogenesis, induced
  • cell growth, induced
Putative upstream phosphatases:
  • PPP2CA (human)
RALA (human) RARKMEDsKEKNGKK S183-p
RALA (mouse) RARKMEDSkEKNGkK S183
RALA (rat) RARKMEDSKEKNGKK S183
K184
ARKMEDsKEKNGKKK
0 1
RALA (human) ARKMEDsKEKNGKKK K184
RALA (mouse) ARKMEDSkEKNGkKK K184-ac
RALA (rat) ARKMEDSKEKNGKKK K184
K189
DsKEKNGKKKRKsLA
0 1
RALA (human) DsKEKNGKKKRKsLA K189
RALA (mouse) DSkEKNGkKKRKSLA K189-ac
RALA (rat) DSKEKNGKKKRKSLA K189
S194-p
NGKKKRKsLAKRIRE
Upstream
Downstream
4 2
Effects on Modified Protein
  • enzymatic activity, induced
  • intracellular localization
  • molecular association, regulation
Effects on Biological Processes:
  • carcinogenesis, induced
  • cell growth, altered
  • cell growth, induced
  • cytoskeletal reorganization
Putative in vivo kinases:
  • AurA (human)
Putative upstream phosphatases:
  • PPP2CA (human)
RALA (human) NGKKKRKsLAKRIRE S194-p
RALA (mouse) NGkKKRKSLAKRIRE S194
RALA (rat) NGKKKRKSLAKRIRE S194